Education
About Us
Working with TipRanks
Follow Us
Sernova (TSE:SVA)
TSX:SVA
SVA Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.15 - C$0.34
Previous CloseN/A
Volume71.45K
Average Volume (3M)135.88K
Market Cap
C$50.92M
Enterprise ValueC$53.54M
Total Cash (Recent Filing)C$1.21M
Total Debt (Recent Filing)C$546.47K
Price to Earnings (P/E)―
Beta-0.42
Next Earnings
Sep 24, 2025EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding328,484,770
10 Day Avg. Volume94,480
30 Day Avg. Volume135,885
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)-3.01
Price to Sales (P/S)0.00
P/FCF Ratio-2.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$3.30Price Target Upside1962.50% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Sernova News
PremiumCompany Announcements
Sernova Biotherapeutics Appoints Interim Chair Amid Strategic Advancements
PremiumCompany Announcements
Sernova’s Cell Pouch Shows Promising Results in Diabetes Trial
PremiumCompany Announcements
Sernova Biotherapeutics Secures $4 Million Loan for Clinical Advancements
Bulls Say, Bears Say
Bulls Say
Clinical TrialsSernova's Phase 1/2 study results are indicative of the trial being on track to succeed and help de-risk any upcoming data readouts and subsequent studies.
Hypothyroidism MarketSubmission of an IND application for the Cell Pouch device in hypothyroidism could address a significant market opportunity estimated at approximately $2.2 billion.
Technology PotentialThe clear clinical benefit in T1D patients, particularly insulin dependence, speaks to the potential of the Cell Pouch device.
Bears Say
CompetitionDeep responses in diabetes patients position the technology for potential commercial success, particularly as competitors exit the space.
Interim DataDespite these data coming from an interim clinical evaluation, these are clear efficacy signals and the safety profile has remained favorable.
Options Prices
Currently, No data available
---
Ownership Overview
4.10% Insiders
―
Mutual Funds
<0.01% Other Institutional Investors
95.90% Public Companies and
Individual Investors
SVA FAQ
What was Sernova’s price range in the past 12 months?
Sernova lowest stock price was C$0.14 and its highest was C$0.34 in the past 12 months.
What is Sernova’s market cap?
Sernova’s market cap is C$50.92M.
When is Sernova’s upcoming earnings report date?
Sernova’s upcoming earnings report date is Sep 24, 2025 which is in 78 days.
How were Sernova’s earnings last quarter?
Sernova released its earnings results on Jun 13, 2025. The company reported -C$0.01 earnings per share for the quarter, beating the consensus estimate of -C$0.021 by C$0.011.
Is Sernova overvalued?
According to Wall Street analysts Sernova’s price is currently Undervalued.
Does Sernova pay dividends?
Sernova does not currently pay dividends.
What is Sernova’s EPS estimate?
Sernova’s EPS estimate is -0.02.
How many shares outstanding does Sernova have?
Sernova has 328,484,770 shares outstanding.
What happened to Sernova’s price movement after its last earnings report?
Sernova reported an EPS of -C$0.01 in its last earnings report, beating expectations of -C$0.021. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Sernova?
Currently, no hedge funds are holding shares in TSE:SVA
Sernova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$3.30 (1962.50% Upside)
C$3.30 (1962.50% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.22%
12-Months-Change
Fundamentals
Return on Equity
248.46%
Trailing 12-Months
Asset Growth
-67.08%
Trailing 12-Months
Company Description
Sernova
Sernova Corp. (SVA) is a clinical-stage regenerative medicine company focused on developing and commercializing therapeutic cell technologies to treat chronic diseases such as diabetes, hemophilia, and thyroid disease. The company is headquartered in Canada and operates within the biotechnology sector. Its core product is the Cell Pouch System, an implantable medical device designed to create a natural environment for the survival and function of therapeutic cells, which can produce necessary proteins or hormones that are deficient in patients.
SVA Stock 12 Month Forecast
Average Price Target
C$3.30
▲(1962.50%Upside)